Is VALN or GHRS more profitable?

GH Research has a net margin of 0.00% compared to Valneva's net margin of -88.87%. GH Research's return on equity of -19.36% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Valneva -88.87% -107.63% -33.02% GH Research N/A -19.36% -18.73%

Does the media prefer VALN or GHRS?

In the previous week, GH Research had 5 more articles in the media than Valneva. MarketBeat recorded 6 mentions for GH Research and 1 mentions for Valneva. Valneva's average media sentiment score of 1.02 beat GH Research's score of 0.47 indicating that Valneva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GH Research 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, NBTX or VALN?

Nanobiotix has higher earnings, but lower revenue than Valneva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $29.64M 65.54 -$27.11M N/A N/A Valneva $197.56M 2.39 -$130.33M -$1.87 N/A

Is NBTX or VALN more profitable?

Nanobiotix has a net margin of 0.00% compared to Valneva's net margin of -88.87%. Nanobiotix's return on equity of 0.00% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A Valneva -88.87% -107.63% -33.02%

Does the media favor NBTX or VALN?

In the previous week, Nanobiotix had 1 more articles in the media than Valneva. MarketBeat recorded 2 mentions for Nanobiotix and 1 mentions for Valneva. Valneva's average media sentiment score of 1.02 beat Nanobiotix's score of 0.67 indicating that Valneva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valneva 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate VALN or MESO?

Valneva presently has a consensus price target of $11.98, indicating a potential upside of 140.95%. Given Valneva's higher possible upside, research analysts plainly believe Valneva is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valneva 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 Mesoblast 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher valuation and earnings, VALN or MESO?

Mesoblast has lower revenue, but higher earnings than Valneva. Mesoblast is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Valneva $197.56M 2.39 -$130.33M -$1.87 N/A Mesoblast $17.20M 107.00 -$102.14M -$0.28 N/A

Is VALN or MESO more profitable?

Mesoblast has a net margin of 0.00% compared to Valneva's net margin of -88.87%. Mesoblast's return on equity of 0.00% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Valneva -88.87% -107.63% -33.02% Mesoblast N/A N/A N/A

Does the media prefer VALN or MESO?

In the previous week, Mesoblast had 2 more articles in the media than Valneva. MarketBeat recorded 3 mentions for Mesoblast and 1 mentions for Valneva. Valneva's average media sentiment score of 1.02 beat Mesoblast's score of 0.00 indicating that Valneva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mesoblast 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to VALN or GLUE?

In the previous week, Monte Rosa Therapeutics had 6 more articles in the media than Valneva. MarketBeat recorded 7 mentions for Monte Rosa Therapeutics and 1 mentions for Valneva. Monte Rosa Therapeutics' average media sentiment score of 1.04 beat Valneva's score of 1.02 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monte Rosa Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VALN or LKFT?

In the previous week, Valneva and Valneva both had 1 articles in the media. Valneva's average media sentiment score of 1.02 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.00 indicating that Valneva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lakefront Biotherapeutics American Depositary Shares 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Valneva (VALN) Competitors

$4.97 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$4.99 +0.02 (+0.40%)

As of 07/31/2026 04:10 PM Eastern

Compare

VALN vs. GHRS, NBTX, MESO, GLUE, and LKFT

Should you buy Valneva stock or one of its competitors? MarketBeat compares Valneva with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Valneva include GH Research (GHRS), Nanobiotix (NBTX), Mesoblast (MESO), Monte Rosa Therapeutics (GLUE), and Lakefront Biotherapeutics American Depositary Shares (LKFT).

How does Valneva compare to GH Research?

Valneva (NASDAQ:VALN) and GH Research (NASDAQ:GHRS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

In the previous week, GH Research had 5 more articles in the media than Valneva. MarketBeat recorded 6 mentions for GH Research and 1 mentions for Valneva. Valneva's average media sentiment score of 1.02 beat GH Research's score of 0.47 indicating that Valneva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GH Research	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Valneva currently has a consensus target price of $11.98, indicating a potential upside of 140.95%. GH Research has a consensus target price of $40.78, indicating a potential upside of 45.27%. Given Valneva's higher possible upside, analysts clearly believe Valneva is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
GH Research	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.67

GH Research has lower revenue, but higher earnings than Valneva. GH Research is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.39	-$130.33M	-$1.87	N/A
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A

GH Research has a net margin of 0.00% compared to Valneva's net margin of -88.87%. GH Research's return on equity of -19.36% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-88.87%	-107.63%	-33.02%
GH Research	N/A	-19.36%	-18.73%

Valneva has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, GH Research has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market.

11.4% of Valneva shares are owned by institutional investors. Comparatively, 56.9% of GH Research shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

GH Research beats Valneva on 9 of the 15 factors compared between the two stocks.

How does Valneva compare to Nanobiotix?

Nanobiotix (NASDAQ:NBTX) and Valneva (NASDAQ:VALN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

Nanobiotix has a net margin of 0.00% compared to Valneva's net margin of -88.87%. Nanobiotix's return on equity of 0.00% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Valneva	-88.87%	-107.63%	-33.02%

Nanobiotix presently has a consensus target price of $37.33, indicating a potential downside of 2.73%. Valneva has a consensus target price of $11.98, indicating a potential upside of 140.95%. Given Valneva's higher probable upside, analysts clearly believe Valneva is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Comparatively, 14.9% of Valneva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Nanobiotix has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Valneva has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

Nanobiotix has higher earnings, but lower revenue than Valneva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$29.64M	65.54	-$27.11M	N/A	N/A
Valneva	$197.56M	2.39	-$130.33M	-$1.87	N/A

In the previous week, Nanobiotix had 1 more articles in the media than Valneva. MarketBeat recorded 2 mentions for Nanobiotix and 1 mentions for Valneva. Valneva's average media sentiment score of 1.02 beat Nanobiotix's score of 0.67 indicating that Valneva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valneva	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Nanobiotix beats Valneva on 9 of the 14 factors compared between the two stocks.

How does Valneva compare to Mesoblast?

Valneva (NASDAQ:VALN) and Mesoblast (NASDAQ:MESO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

Mesoblast has a net margin of 0.00% compared to Valneva's net margin of -88.87%. Mesoblast's return on equity of 0.00% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-88.87%	-107.63%	-33.02%
Mesoblast	N/A	N/A	N/A

Mesoblast has lower revenue, but higher earnings than Valneva. Mesoblast is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.39	-$130.33M	-$1.87	N/A
Mesoblast	$17.20M	107.00	-$102.14M	-$0.28	N/A

Valneva has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Mesoblast has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market.

11.4% of Valneva shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Comparatively, 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Mesoblast had 2 more articles in the media than Valneva. MarketBeat recorded 3 mentions for Mesoblast and 1 mentions for Valneva. Valneva's average media sentiment score of 1.02 beat Mesoblast's score of 0.00 indicating that Valneva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Valneva presently has a consensus price target of $11.98, indicating a potential upside of 140.95%. Given Valneva's higher possible upside, research analysts plainly believe Valneva is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Mesoblast beats Valneva on 11 of the 17 factors compared between the two stocks.

How does Valneva compare to Monte Rosa Therapeutics?

Valneva (NASDAQ:VALN) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Valneva has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market.

In the previous week, Monte Rosa Therapeutics had 6 more articles in the media than Valneva. MarketBeat recorded 7 mentions for Monte Rosa Therapeutics and 1 mentions for Valneva. Monte Rosa Therapeutics' average media sentiment score of 1.04 beat Valneva's score of 1.02 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monte Rosa Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Valneva currently has a consensus target price of $11.98, indicating a potential upside of 140.95%. Monte Rosa Therapeutics has a consensus target price of $32.33, indicating a potential upside of 95.72%. Given Valneva's higher possible upside, research analysts plainly believe Valneva is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Monte Rosa Therapeutics	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.56

11.4% of Valneva shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valneva has a net margin of -88.87% compared to Monte Rosa Therapeutics' net margin of -302.69%. Monte Rosa Therapeutics' return on equity of -40.99% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-88.87%	-107.63%	-33.02%
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%

Monte Rosa Therapeutics has lower revenue, but higher earnings than Valneva. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.39	-$130.33M	-$1.87	N/A
Monte Rosa Therapeutics	$123.67M	11.28	-$38.63M	-$1.48	N/A

Summary

Monte Rosa Therapeutics beats Valneva on 10 of the 16 factors compared between the two stocks.

How does Valneva compare to Lakefront Biotherapeutics American Depositary Shares?

Valneva (NASDAQ:VALN) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Valneva. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.39	-$130.33M	-$1.87	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.04B	1.72	$363.05M	-$1.41	N/A

Valneva has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

Valneva currently has a consensus price target of $11.98, suggesting a potential upside of 140.95%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $34.33, suggesting a potential upside of 26.18%. Given Valneva's stronger consensus rating and higher possible upside, analysts plainly believe Valneva is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.11

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Valneva's net margin of -88.87%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-88.87%	-107.63%	-33.02%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

In the previous week, Valneva and Valneva both had 1 articles in the media. Valneva's average media sentiment score of 1.02 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.00 indicating that Valneva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakefront Biotherapeutics American Depositary Shares	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.4% of Valneva shares are held by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 14.9% of Valneva shares are held by insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Valneva and Lakefront Biotherapeutics American Depositary Shares tied by winning 8 of the 16 factors compared between the two stocks.

Get Valneva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VALN vs. The Competition

Export

Metric	Valneva	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$471.60M	$3.54B	$6.85B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-2.66	7.38	282.28	24.66
Price / Sales	2.39	1,199.83	563.21	75.35
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	3.58	16.96	10.96	6.07
Net Income	-$130.33M	-$12.56M	$3.49B	$347.99M
7 Day Performance	0.20%	-1.80%	-0.63%	-0.44%
1 Month Performance	-4.79%	-8.44%	-5.23%	-4.81%
1 Year Performance	-31.16%	48.63%	62.07%	18.61%

Valneva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VALN Valneva	2.8344 of 5 stars	$4.97 flat	$11.98 +140.9%	-31.2%	$471.60M	$197.56M	N/A	700	Positive News Gap Up
GHRS GH Research	2.1889 of 5 stars	$27.96 +0.8%	$40.78 +45.8%	+104.3%	$1.92B	N/A	N/A	10	Upcoming Earnings
NBTX Nanobiotix	1.3159 of 5 stars	$37.82 -5.9%	$37.33 -1.3%	+469.9%	$1.91B	$29.64M	N/A	100	Gap Up
MESO Mesoblast	0.3351 of 5 stars	$14.45 -0.8%	N/A	-6.6%	$1.87B	$17.20M	N/A	80	Gap Up
GLUE Monte Rosa Therapeutics	3.2393 of 5 stars	$22.04 -2.3%	$34.83 +58.0%	+244.9%	$1.86B	$123.67M	N/A	90	Positive News Upcoming Earnings Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VALN) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Valneva (VALN) Competitors